Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | DNM1 | Q05193 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | IDO1 | P14902 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.37 |
| ▸ | F10 | P00742 | 1/20 | 0.37 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12075395 | 0.89 | LMNA (0.42) | SMN1; SMN2IDO1MEN1KMT2AMAPT | |
| SCHEMBL19571325 | 0.87 | MEN1 (0.43) | SMN1; SMN2NPC1MEN1KMT2AKDM4E | |
| SCHEMBL12288 | 0.85 | DNM1 (0.40) | CHRM2DNM1SMN1; SMN2NPC1IDO1 | |
| SCHEMBL20124146 | 0.85 | ANPEP (0.37) | DNM1ALDH1A1LMNAF2 | |
| SCHEMBL14853353 | 0.85 | DNM1 (0.49) | CHRM2DNM1SMN1; SMN2NPC1IDO1 | |
| SCHEMBL11981656 | 0.84 | ANPEP (0.50) | CHRM2DNM1MEN1KMT2AMAPT | |
| SCHEMBL11774 | 0.84 | ANPEP (0.56) | DNM1MEN1KMT2ALMNA | |
| SCHEMBL11729 | 0.84 | NPC1 (0.42) | CHRM2DNM1SMN1; SMN2NPC1IDO1 | |
| SCHEMBL4100287 | 0.82 | IDO1 (0.52) | SMN1; SMN2NPC1IDO1MEN1KMT2A | |
| SCHEMBL12094 | 0.81 | NPC1 (0.40) | CHRM2DNM1SMN1; SMN2NPC1IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9845297-B2 | Antimicrobial compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2017-12-19 | — | — | US | disclosed |
| US-20170320892-A1 | Antimicrobial Compounds And Methods Of Making And Using The Same | SILICON VALLEY BANK | 2017-11-09 | — | — | US | disclosed |
| US-9573962-B2 | Antimicrobial compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-20160031893-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | BioVersys AG (CH) | 2016-02-04 | — | — | US | disclosed |
| US-20160031828-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | SILICON VALLEY BANK | 2016-02-04 | — | — | US | disclosed |
| US-9216979-B2 | Antimicrobial compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2015-12-22 | — | — | US | disclosed |
| US-9193731-B2 | Antimicrobial compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-20150274752-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | SILICON VALLEY BANK | 2015-10-01 | — | — | US | disclosed |
| US-9023843-B2 | Antimicrobial compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| US-20130090326-A1 | Antimicrobial Compounds and Methods of Making and Using the Same | RIB-X PHARMACEUTICALS, INC. (US) | 2013-04-11 | — | — | US | disclosed |
| WO-2011047323-A2 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | RIB-X PHARMACEUTICALS, INC. (US) | 2011-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130090326-A1 | Antimicrobial Compounds and Methods of Making and Using the Same | MPO, LPO, CAT | CHRM2 4820/4885DNM1 217/4885SMN1; SMN2 3979/4885 |
| US-20150274752-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | LPO, MPO, CAT | CHRM2 4814/4885DNM1 200/4885SMN1; SMN2 3970/4885 |
| US-20160031893-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | MPO, LPO, CAT | CHRM2 4820/4885DNM1 217/4885SMN1; SMN2 3979/4885 |
| US-20160031828-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | MPO, LPO, CAT | CHRM2 4820/4885DNM1 217/4885SMN1; SMN2 3979/4885 |
| US-20170320892-A1 | Antimicrobial Compounds And Methods Of Making And Using The Same | LPO, MPO, CAT | CHRM2 4814/4885DNM1 200/4885SMN1; SMN2 3970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.